Neurocrine Biosciences (NBIX)
Develops and commercializes neuroscience and rare-disease medicines led by INGREZZA.
Something off on this page? Send us feedback.
Markets INGREZZA for movement disorders, CRENESSITY for congenital adrenal hyperplasia, and VYKAT XR for Prader-Willi syndrome. U.S. product sales anchor the business, supplemented by partner royalties, while INGREZZA remains the dominant commercial asset.
Commercializes INGREZZA for tardive dyskinesia and Huntington's-disease chorea, CRENESSITY for classic congenital adrenal hyperplasia, and VYKAT XR for hyperphagia in Prader-Willi syndrome. The portfolio spans movement disorders and rare endocrine and genetic disease.
Operates primarily in the United States, where most employees are based and its core brands are sold. Royalties from AbbVie-marketed ORILISSA and ORIAHNN and regional valbenazine licenses add partner-commercialized economics. Drug discovery and development extend into psychiatry and gene therapy through internally led and licensed programs.
Execution rests on translating neuroscience research into approved medicines and building focused commercial franchises around them. INGREZZA remains the dominant commercial asset; the business also depends on collaborators for parts of its pipeline and overseas commercialization. A U.S. Department of Justice inquiry concerns INGREZZA sales and marketing, with timing and outcome unresolved.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 11, 2026 | Morgan Stanley | Reiterate | Rating: —Target: $182 | Target: $183 |
| Sep 8, 2026 | RBC Capital | Reiterate | Rating: —Target: $195 | Target: $198 |
| Aug 13, 2026 | Bernstein | Target | Target: $221 | Target: $218 |
| Aug 13, 2026 | Morgan Stanley | Reiterate | Rating: —Target: $196 | Target: $182 |
| Aug 13, 2026 | Deutsche Bank | Target | Target: $190 | Target: $165 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $389.8M · Total debt $401.8M · Total assets $5.36B · Shareholders' equity $3.69B
- Revenue
- $959.0M
- Operating income
- $153.0M
- Net income
- $144.4M
No dividends on record.
| Institutions | ≈ 99.19% | 100.82M shares | |
|---|---|---|---|
| 796 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 8.51% | 8.65M shares | |
| 22 holders · as of Sep 15, 2026 | |||
| Adds to | 107.70% | ||
101.65M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 107.70%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BlackRock, Inc.Institution | 13.49% | 13.71M | as of Jun 30, 2026 |
Ein #.Insider | 7.33% | 7.45M | filed Feb 10, 2022 |
JPMorgan Chase & CoInstitution | 6.29% | 6.40M | as of Jun 30, 2026 |
Dodge & CoxInstitution | 5.49% | 5.58M | as of Jun 30, 2026 |
Vanguard Portfolio Management LLCInstitution | 4.89% | 4.97M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 14, 2026 | Matt Abernethy | officer: Chief Financial Officer | −2,311 | $157.20 |
| Sep 14, 2026 | David W. Boyer | officer: Chief Corp. Affairs Officer | −826 | $157.45 |
| Sep 9, 2026 | Eric Benevich | officer: Chief Commercial Officer | −2,154 | $154.61 |
| Jul 28, 2026 | Leslie V. Norwalk | director | −1,250 | $182.01 |
| Jul 9, 2026 | Darin Lippoldt | officer: Chief Legal Officer | −10,000 | $179.60 |
- Teva (ADR)
Direct VMAT2 rival in tardive dyskinesia and Huntington’s chorea
- Bristol-Myers Squibb
Commercial muscarinic benchmark for Phase 3 schizophrenia program
- Aardvark Therapeutics
Paused Phase 3 hyperphagia rival in Prader-Willi syndrome
- Rhythm Pharmaceuticals
Clinical-stage MC4R programs for Prader-Willi hyperphagia
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Neurocrine Biosciences | $142.96 | −0.69% | $14.48B | 21.1 | 15.7 | 4.3 | +39.5% |
| Teva (ADR) | $39.12 | −2.35% | $46.66B | 66.8 | 13.9 | 2.7 | −0.8% |
| Bristol-Myers Squibb | $62.74 | +0.18% | $127.91B | 13.8 | 9.8 | 2.6 | +5.7% |
| Aardvark Therapeutics | $5.72 | +2.69% | $121.9M | — | — | — | — |
| Rhythm Pharmaceuticals | $100.60 | +1.79% | $6.78B | — | — | 28.3 | +46.9% |
| Median | 40.3 | 11.9 | 2.7 | +5.7% |